BlackBerry Limited (NASDAQ: BBRY) just keeps continuing to amaze on the upside. It was not that long ago that it was hitting 52-week lows under $5.50, and on Friday the stock has already challenged the $9.00 mark.
John Chen’s actions here may only be part of the action. The stock of the struggling smartphone player is up a sharp 20% from the $7.44 price at the end of 2013. Friday actually marks the second trading day of the twelve trading days of 2014 that we have seen the stock go above $9.00.
Citron Research is usually known for its short sell idea focused articles, but the research shop has shown that the short selling mentality here needs to be dropped.�A short squeeze could drive BlackBerry shares even higher, maybe even up to $15. Citron’s report is a 12-page reversal of fortune report. Again, Citron is often known for being negative on companies.
Blackberry shares were up 4.4% at $8.94 on almost 20 million shares. The 52-week trading range is $5.44 to $18.32.
Best Wireless Telecom Stocks To Watch Right Now: Xcel Energy Inc.(XEL)
Xcel Energy Inc., through its subsidiaries, engages in the generation, purchase, transmission, distribution, and sale of electricity to residential, commercial, and industrial customers, as well as to public authorities in the United States. The company generates electricity using coal, nuclear, natural gas, hydro, wood, diesel, and wind energy. It also engages in the purchase, transportation, distribution, and sale of natural gas to residential, commercial, and industrial customers. The company serves customers in portions of Colorado, Michigan, Minnesota, New Mexico, North Dakota, South Dakota, Texas, and Wisconsin. As of December 31, 2010, it provided electricity services to 3,391,611 customers; and natural gas services to 1,893,250 customers. Xcel Energy, through its joint venture interests in WYCO Development LLC, develops and leases natural gas pipeline, storage, and compression facilities. The company was founded in 1909 and is based in Minneapolis, Minnesota.
Advisors' Opinion:- [By David Dittman]
Xcel Energy Inc�� (NYSE: XEL) coal-fired generation was 42.3 percent of its total 2013output. Xcel was down 0.2 percent.
NRG Energy Inc�� (NYSE: NRG) 2013 coal-fired share of generation was 28.8 percent, but it�� been actively adding renewable sources. Its stock was up 2.2 percent. NextEra Energy Inc (NYSE: NEE), owner/operator of the largest fleet of renewable generation in the US with just 1.7 percent of its output from coal, was up 2.8 percent.
- [By Richard Stavros]
In fact, investment opportunities in this niche could soon be on the rise. Several utilities have been considering creating standalone transmission companies this year, including Xcel Energy Inc (NYSE: XEL). But whether it’s a standalone company or the sale of transmission assets to a transmission company, regulatory approval will still be key. For instance, regulators declined Entergy Corp’s (NYSE: ETR) sale of its transmission assets to transmission company ITC Holdings Corp (NYSE: ITC) in 2013.
- [By Justin Loiseau]
Xcel excels at cutting carbon
Xcel Energy (NYSE: XEL ) announced today that it expects to surpass its goal of a 20% CO2 reduction by 2020 by up to 7%. Xcel has favored wind as its main method for getting rid of greenhouse gases. The utility currently owns 4,900 MW of wind capacity, approximately 12% of its total generation portfolio.
Best Heal Care Companies To Own For 2014: Ormat Technologies Inc.(ORA)
Ormat Technologies, Inc., together with its subsidiaries, engages in the geothermal and recovered energy power business in the United States and internationally. The company operates in two segments, Electricity and Product. The Electricity segment develops, builds, owns, and operates geothermal and recovered energy-based power plants; and sells the electricity. The Product segment designs, manufactures, and sells power units for geothermal and recovered energy-based electricity generation; fossil fuel powered turbo-generators; and heavy duty direct-current generators. It also provides services relating to the engineering, procurement, construction, operation, and maintenance of geothermal and recovered energy power plants. This segment serves contractors and geothermal power plant owners and operators; and interstate natural gas pipeline owners and operators, gas processing plant owners and operators, cement plant owners and operators, and companies in other energy-intens ive industrial processes. The company was founded in 1965 and is based in Reno, Nevada. Ormat Technologies, Inc. is a subsidiary of Ormat Industries Ltd.
Advisors' Opinion:- [By John Udovich]
Small cap Ocean Power Technologies Inc (NASDAQ: OPTT) just sank 34% on news that they have fired their CEO "for cause,��meaning its worth taking a closer look at the stock to see if there is anything to salvage (shares were rising more than 6% in after hours) plus take a look at the performance of potential renewable energy related peers like Ormat Technologies, Inc (NYSE: ORA), Broadwind Energy Inc (NASDAQ: BWEN) and China Ming Yang Wind Power Group Ltd (NYSE: MY).
Best Heal Care Companies To Own For 2014: ChemoCentryx Inc (CCXI)
ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. The Company targets the chemokine system, a network of molecules, including chemokine ligands and their associated receptors, as well as related chemo-attractant receptors, all of which are known to drive inflammation. As of December 31, 2011, the Company had four drug candidates in clinical development. Its drug candidates include Traficet-EN (CCX282, GSK'786 or vercirnon), CCX140, CCX354, CCX168, CCX872, CCX507 and CCX662. The Company is also advancing several additional independent drug candidates through preclinical development. The Company�� wholly owned subsidiary is ChemoCentryx Limited.
The Company's drug candidate Traficet-EN (CCX282, GSK'786), is to control the inflammatory response underlying IBD by targeting the chemokine receptor known as CCR9. The Company has completed nine clinical trials with Traficet-EN in a total of 785 subjects, including five Phase I clinical trials (three in the United States and two in the United Kingdom), one thorough QT study in the United States (an assessment of cardiovascular safety which is required for regulatory approval), and three Phase II clinical trials (one in the Netherlands, the United Kingdom, and the United States, one in Finland and one (PROTECT-1) in Australia, Austria, Belgium, Brazil, Bulgaria, Canada, the Czech Republic, Denmark, France, Germany, Hungary, Israel, the Netherlands, Poland, South Africa, Sweden and the United Kingdom). As of December 31, 2011, the Company�� Traficet-EN drug candidate is in four pivotal Phase III clinical trials being conducted by its partner Glaxo Group Limited (GSK).
The Company's independent drug candidate CCX140, targets the chemokine receptor known as CCR2. CCX140 is a potent and selective antagonist of CCR2 that is found on subsets of monocytes and macrophages, which are cells of th! e immune system. In January 2011, the Company completed a 159-patient randomized Phase II clinical trial, conducted in Australia, the Czech Republic, Germany, Hungary and New Zealand, to assess the safety and tolerability of CCX140 in patients with type 2 diabetes. In addition, CCX140 demonstrated biological activity through a dose-dependent decrease in fasting plasma glucose.
CCX354 targets the chemokine receptor known as CCR1. Synovial fluid from the joints of rheumatoid arthritis (RA) patients contains high levels of activated CCR1 chemokine ligands. The Company completed two Phase I clinical trials in a total of 84 healthy subjects, conducted in Switzerland followed by a Phase I/II clinical trial in 24 patients with stable RA, conducted in Belgium and Romania, and a Phase II proof-of-concept clinical trial in 160 patients with moderate-to-severe RA, conducted in Belgium, the Czech Republic, Germany, Hungary, Poland, Romania and the Ukraine. GSK exercised its option to further develop and commercialize CCX354 in November 2011 and had an exclusive right to initiate a Phase II b clinical trial for CCX354 in RA.
CCX168 targets the chemo-attractant C5a receptor (C5aR), which binds to a biologically activated fragment of the complement protein known as C5. As of December 31, the Company completed a Phase I clinical trial for CCX168, conducted in Switzerland. The Company initiated a Phase II proof-of-concept clinical trial in AAV in the fourth quarter of 2011. Its CCX872 is an independent next generation CCR2 drug candidate for the treatment of metabolic diseases, its CCX507 is an independent drug candidate for the treatment of inflammatory bowel disease (IBD) and CCX662 is an independent drug candidate for the treatment of glioblastoma multiforme (GBM).
The Company competes with Abbott Laboratories, Amgen Inc, AstraZeneca plc, Biogen Idec Inc, Bayer AG, Elan Corporation plc, Glaxo Group Limited, Merck & Co Inc, Merck Serono, Takeda Pharmaceutical Co Ltd, Novartis AG! , Pfizer ! Inc, Reata Pharmaceuticals, Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd, Bristol-Myers Squibb, Incyte Corp and UCB Pharma.
Advisors' Opinion:- [By CRWE]
ChemoCentryx, Inc. (Nasdaq:CCXI), reported that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the BioCentury NewsMakers in the Biotech Industry Conference on Friday, September 7, 2012, at 9:30 a.m. Eastern Time at the Millennium Broadway Hotel & Conference Center in New York, NY.
- [By James E. Brumley]
The last few weeks haven't been particularly encouraging for Crohn's disease sufferers. In August, GlaxoSmithKline (NYSE: GSK) and ChemoCentryx (NASDAQ:CCXI) reported that a jointly-developed Crohn's drug, vercirnon, had failed to meet its late-stage trial endpoints. Though the in-development drug isn't dead in the water (GSK and CCXI could rework the drug, the testing regimen, or use it for other indications), it doesn't look good. Then this month - just a few days ago - Coronado Biosciences Inc. (NASDAQ:CNDO) reported that its Phase 3 trials of Crohn's disease drug TSO had also failed to meet its primary endpoints as well. Like vercirnon, CNDO isn't completely out of luck here with the treatment, but forging ahead with further development of the treatment is grasping at straws. Crohn's sufferers don't need to give up home just yet, however - TNI Biotech Inc. (OTCMKTS:TNIB) appears to have a Crohn's treatment that works, and should be able to sidestep the problems that plagued ChemoCentryx, GlaxoSmithKline, and Coronado Biosciences.
Best Heal Care Companies To Own For 2014: Doral Financial Corporation (DRL)
Doral Financial Corporation operates as a bank holding company for Doral Bank that provides retail banking services to general public and institutions. It operates through four segments: Puerto Rico, the United States, Liquidating Operations, and Treasury. The company accepts deposits; obtains borrowings; originates and invests in loans, including residential real estate mortgage loans; invests in mortgage-backed securities and other investment securities; and offers traditional banking services. It also offers commercial and construction loan products; and purchases assigned interests in senior credit facilities from the syndicated leverage loan market in the United States. In addition, the company provides consumer loans, such as consumer credit, personal loans, loans on savings deposits, and other consumer loans. Further, it offers commercial real estate loans; commercial loans, including lines of credit and term facilities, and working capital for specific purposes, su ch as to finance the purchase of assets, equipment, or inventory; and construction lending products, as well as industrial and land loans. Additionally, the company originates, purchases, and sells mortgage loans; and offers property, casualty, life, and title insurance products primarily to its mortgage loan customers. It operates a network of 26 branches in Puerto Rico; 3 branches in the metropolitan area of New York; and 5 branches in the northwest area of Florida. Doral Financial Corporation was founded in 1972 and is based San Juan, Puerto Rico.
Advisors' Opinion:- [By Jayson Derrick]
An attorney at Doral (NYSE: DRL) stated that the company has “not left negotiations” with Puerto Rico's Treasury. Shares lost 2.86 percent, closing at $8.15.
- [By John Udovich]
For investors looking for exposure to the US commonwealth of Puerto Rico, banking stocks Doral Financial Corp (NYSE: DRL), First Bancorp (NYSE: FBP), OFG Bancorp (NYSE: OFG) and Popular Inc (NASDAQ: BPOP) offer the best bet as these Puerto Rico stocks trade on major US exchanges rather than the OTC. However, it should be mentioned that there has been a slowdown in Puerto Rico�� economy which has also shrunk in five of the past seven fiscal years. Then last�February, Puerto Rico�� debt was cut to speculative grade by the three largest credit-rating companies while�Governor Alejandro Garcia Padilla has proposed a series of budget cuts to help tackle the island�� mounting debt load -including the freezing public workers��salaries and the closing about 100 schools.
Best Heal Care Companies To Own For 2014: Anika Therapeutics Inc.(ANIK)
Anika Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and commercializes therapeutic products for tissue protection, healing, and repair. Its products are based on hyaluronic acid (HA), a naturally occurring biocompatible polymer found in the body. The company offers orthobiologics products for providing relief from the pain of osteoarthritis, and regenerating damaged tissue, such as cartilage defects; ORTHOVISC for the treatment of osteoarthritis of the knee and various joints; ORTHOVISC mini for the treatment of osteoarthritis in small joints; and MONOVISC, a single injection product used for the treatment of osteoarthritis in various joints. It also provides wound care products that comprise Hyalograft 3D for the regeneration of skin; and Hyalomatrix for the treatment of burns and ulcers. In addition, the company offers AMVISC, AMVISC Plus, STAARVISC-II, Optivisc, and AnikaVisc which are injectable HA products used as viscoelastic agents in o phthalmic surgical procedures, such as cataract extraction and intraocular lens implantation. Further, it provides INCERT, a HA based product for the prevention of post-surgical adhesions; Hyalobarrier and Hyalobarrier Endo, which are post operative adhesion barriers for abdominal indications; and HYVISC, an injectable HA product used for the treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine osteoarthritis. Additionally, the company offers Merogel, a product used for the treatment of ear, nose, and throat disorders; and provides dermal fillers for facial wrinkles and scar remediation under the ELEVESS and HYDRELLE brand names. It markets its products directly, as well as through a network of distributors primarily in the United States and Europe. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
Advisors' Opinion:- [By STOCKPICKR]
Anika Therapeutics (ANIK), together with its subsidiaries, develops, manufactures, and commercializes therapeutic products for tissue protection, healing, and repair in the U.S., Europe, and internationally. This stock closed up 2.1% to $48.86 in Monday's trading session.
Monday's Volume: 1.25 million
Three-Month Average Volume: 347,160
Volume % Change: 272%From a technical perspective, ANIK jumped higher here right above some near-term support at $46 with above-average volume. This spike higher on Monday briefly pushed shares of ANIK into breakout territory, since the stock flirted with some near-term overhead resistance levels at $49.21 to $49.37. Shares of ANIK tagged an intraday high of $51.40, before it closed below that level at $48.86. Market players should now look for a continuation move to the upside in the short-term if ANIK manages to take out Monday's high of $51.36 to its 52-week high of $52.49 with high volume.
Traders should now look for long-biased trades in ANIK as long as it's trending above Monday's low of $47.57 or above $46 and then once it sustains a move or close above $51.36 to $52.49 with volume that hits near or above 347,160 shares. If that move begins soon, then ANIK will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that move are $55 to $60.
Best Heal Care Companies To Own For 2014: Allison Transmission Holdings Inc (ALSN)
Allison Transmission Holdings, Inc. (Allison), incorporated on June 22, 2007, designs and manufactures commercial and military fully-automatic transmissions. The Company is a manufacturer of fully-automatic transmissions for medium- and heavy-duty commercial vehicles, medium- and heavy-tactical the United States military vehicles and hybrid-propulsion systems for transit buses. Allison transmissions are used in a range of applications, including on-highway trucks (distribution, refuse, construction, fire and emergency), buses (primarily school and transit), motorhomes, off-highway vehicles and equipment (energy and mining) and military vehicles (wheeled and tracked). In January 2014, the Company opened a facility in the Netherlands to serve customers across Europe, the Middle East and Africa.
Allison transmissions are sold under the Allison Transmission brand name and remanufactured transmissions are sold under the ReTran brand name. The Company has 12 transmission product lines with over 100 different product models. Allison transmissions are included in more than 2,500 vehicle configurations, which are compatible with more than 500 combinations of engine brands, models and ratings globally. In addition to the Company's product offerings, the Company has products under development, including the TC10, a Class 8 metro truck fully-automatic transmission, and the H 3000 and the H 4000 hybrid-propulsion systems designed for use in medium- and heavy-duty commercial trucks and buses.
North America
The Company is a manufacturer of fully-automatic transmissions for the on-highway medium- and heavy-duty commercial vehicle markets in North America. The Company's core North American on-highway market includes Class 4-5, Class 6-7 and Class 8 straight trucks, conventional transit, shuttle and coach buses, school buses and motorhomes. Class 8 trucks are subdivided into two markets: straight and tractor. The Company sells its transmissions in the North American on-highway mar! ket to original equipment manufacturers (OEMs), including Blue Bird, Daimler, Hino, Navistar, PACCAR, Spartan Motors and Volvo. These OEMs, in turn, install the Company's transmissions in vehicles in which its transmission is either the exclusive transmission available or is specifically requested by end users who are choosing between a manual transmission, an AMT or a fully-automatic transmission. The Company's vehicle class in North America include Class 4-5 Trucks, Class 6-7 Trucks, Class 8 Straight Trucks, Buses and
Motorhomes
Class 4-5 trucks are used in urban applications, including distribution, commercial lease and rental, as well as ambulance. The Company is the transmission supplier to the Navistar Class 4-5 TerraStar truck. Class 6-7 trucks are used in urban applications, including larger distribution, commercial lease and rental, ambulance, rescue and fire trucks. The Company's transmissions are used in Class 6-7 buses. The Company supplies its transmissions for all of the school buses produced in North America. The bus market also encompasses non-hybrid transit and conventional coach and shuttle buses. The Company sells its transmissions for use in larger motorhomes ( types A). The Company typically sells to the chassis manufacturers, such as Navistar and Daimler, that supply body manufacturers, such as Thor Industries, Winnebago Industries and Fleetwood RV. As of December 31, 2012, the Company has delivered over 5,000 H 40/50 EP hybrid-propulsion transit bus systems globally to 246 cities in 14 countries. The Company's customers in this North American end market are typically city, state and federal governmental entities. The Company has provided products used in vehicles and equipment, which serve energy, mining and construction applications. Its customers include Halliburton Company, Baker Hughes, Weatherford International, National Oilwell Varco, and Key Energy Services. The Company also provides heavy-duty transmissions used in mining trucks, specialty and co! nstructio! n vehicles. Mining applications include trucks used to haul various commodities and other products, including rigid dump trucks, underground trucks and long-haul tractor trailer trucks with load capacities between 40 to 110 tons. Specialty vehicles using the Company's heavy-duty transmissions include airport rescue and firefighting vehicles and heavy-equipment transporters.
Outside North America
The Company is a manufacturer of fully-automatic transmissions for the commercial vehicle markets outside of North America. Within Europe, the Company serves Western European developed markets, as well as Russian and Eastern European emerging markets. The Company's on-highway customers in these markets are Daimler, Iveco, Scania, and Volvo. Fully-automatic transmission technology has approximately a 6% market share in European truck applications. The Company supplies transmissions to European OEMs. The Company is the exclusive transmission in refuse chassis with Daimler, Dennis Eagle and Renault SA. The Company also supply mining OEMs, such as Atlas Copco UK, Perlini Equipment, Sandvik AB and Terex. As of December 31, 2012, in China, the Company is the provider of fully-automatic commercial vehicle transmissions with a substantial installed base of over 45,000 Allison transmissions, including 30,000 units in transit buses, operated by 90 different bus fleets in 55 cities. The Company's off-highway transmissions are also used in China for energy, mining and construction, by OEM customers including 4th Petroleum and Yantai Jereh Oilfield Services Group Co. in energy applications and Qinhuangdao Tolian Speciality Transporter Co., Sany Group Co. and North Hauler in mining and construction applications. Australia and South Korea have OEMs with domestic production capabilities for which the Company is a supplier, including Iveco, Hyundai Motor Company and Daewoo International Corporation.
Military
The Company sells all of the transmissions for medium- and heavy-tac! tical whe! eled vehicle platforms, including the Family of Medium Tactical Vehicles, Armored Security Vehicles, Heavy Expanded Mobility Tactical Trucks, Heavy Equipment Transporters, Palletized Loading Systems, M915 Series Trucks, Medium Tactical Vehicle Replacements and the Logistic Vehicle System Replacement. In addition, the Company supplied transmissions for Mine-Resistant Ambush Protected (MRAP) Vehicles and the MRAP All Terrain Vehicle and for all three potential manufacturers of the Joint Light Tactical Vehicles. Transmissions for the Company's wheeled vehicle platforms are sold to OEMs, including BAE, Daimler, General Dynamics Land Systems, Oshkosh, Navistar and Textron Marine & Land Systems.
The Company is the supplier on two of the three key tracked vehicle platforms, the Abrams tank and the M113 family of vehicles, which are sold directly to the United States military. Additionally, the Company sells parts kits to licensees for the production of transmissions for tracked vehicles manufactured outside North America. The Company has been selected as the transmission supplier for the prime contractors bidding for the United States Army ground combat vehicle.
Service Parts, Support, Equipment and Other (Aftermarket)
Aftermarket provides the Company with a source of revenues as the installed base of vehicles and equipment utilizing the Company's transmissions. The Company has assembled a global network of approximately 1,400 distributor and dealer locations to sells, service and support its transmissions. As part of the Company's brand strategy, its independent distributors and dealers are required to sell genuine Allison-branded parts. The Company offers remanufactured transmissions under its ReTran brand. The Company also provides support equipment to its OEMs to assist in installing new Allison transmissions into vehicles.
The Company competes with Ford Motor Company, Eaton Corp., Voith GmbH, ZF Friedrichshafen AG, BAE, Caterpillar Inc., Twin Disc, Inco! rporated,! Komatsu, Ltd., Aisin Seiki Co., Ltd., JATCO Ltd, Mitsubishi Fuso Truck and Bus Corporation, Hino, Isuzu and Nissan Diesel, Danyang Winstar Auto Parts Co., Ltd., Tata, Ashok Leyland, JCBL Ltd., Asia Motor Works Limited, BEML, Renk AG and L-3 Communications Corporation.
Advisors' Opinion:- [By Rich Duprey]
Approving an increase in the quarterly cash dividend paid to shareholders, transmission manufacturer Allison Transmissions (NYSE: ALSN ) �announced today that its board of directors doubled the payout from�$0.06�per share to�$0.12�per share while also providing preliminary estimates for its first quarter, which ended March 31.
- [By Ben Levisohn]
2Q14 Machinery results are likely to reflect what we view as a still mixed but improving macroeconomic environment that we think could support pockets of strength in Machinery end markets. In particular, we think both North American truck and North American energy markets continue to improve while global construction markets look supportive of continued solid/better-than-expected results (mostly from improved margin) in Caterpillar’s Construction segment. Solid truck, energy and construction markets seem supportive of earnings for Caterpillar as well as truck suppliers Cummins (CMI) and Allison Transmission Holdings (ALSN)…
No comments:
Post a Comment